One Year After ODAC Decision: Myeloma Studies Move to Adopt MRD End Point
In the last year, there has been excitement about the use of MRD in multiple myeloma trials and new approaches to assessing clinical outcomes in patients.
Related Articles
KEYNOTE-564: Favorable Long-Term Safety With Adjuvant Pembrolizumab in RCC
Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.
Cilta-Cel Bests SOC in Refractory Multiple Myeloma
Cilta-cel therapy significantly enhances survival rates in lenalidomide-refractory multiple myeloma, outperforming standard treatments in recent trials.
Improving Caregiver Quality of Life: From Clinician-Led to Digital Intervention
Jamie Jacobs, PhD, provides background on a digital intervention for caregivers of patients undergoing bone marrow transplant.
Adjuvant Pembrolizumab in Kidney Cancer: Dr Haas on KEYNOTE-564
Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.
Roundtable Roundup: Adjuvant Therapy for HR+, HER2- Breast Cancer
In separate, live virtual events, William J. Gradishar, MD; and Tiffany A. Traina, MD, discussed multiple scenarios for a patient with hormone receptor–positive, HER2-negative breast…
Subgroup Data Sustain Cadonilimab Survival Benefit in Cervical Cancer
The survival benefit with cadonilimab in cervical cancer in the overall phase 3 COMPASSION-16 study population was sustained across prespecified subgroups.
Nine Staff Management Essentials for Physicians
Discover essential strategies for physicians to enhance team management in medical practices, fostering efficiency and improving patient care.
Atebimetinib Combination Shows Promising Survival Data in Pancreatic Cancer
New trial data reveals atebimetinib combined with gemcitabine/nab-paclitaxel significantly improves survival rates in pancreatic cancer patients.
Plasma Epigenomics in mCRPC: Predicting PSMA-Targeted Therapy
Jacob E. Berchuck, MD, discusses research on plasma epigenomic profiling in metastatic castration-resistant prostate cancer.
FDA Grants Orphan Drug Designation to SENTI-202 for R/R AML
SENTI-202, a groundbreaking CAR NK-cell therapy, targets relapsed/refractory AML, offering hope for patients with limited treatment options.